Yahoo Finance 
Merck & Co., Roche, and BMS Among Leading Players in the Non-Small Cell Lung Cancer Drugs Market | GlobalData Plc
Merck & Co. currently holds the position as the market leader based on the success of its agent Keytruda in multiple patient populations and across the 8MM
LONDON, July 20, 2022 (GLOBE NEWSWIRE) -- The “Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2029” report offered by GlobalData provides an overview of NSCLC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Additionally, the report analyses topline NSCLC market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
The sales of NSCLC therapeutics totaled $19.2 billion in 2019 in the 8MM. The market is anticipated to experience growth at a CAGR of more than 5% by 2029. This growth is driven by the anticipated approval and launch of 29 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM.
For more detailed statistics on NSCLC market sizing and forecast, download a sample report
NSCLC Drugs Market Drivers
GlobalData anticipates the launch of 29 pipeline products across the 8MM: abivertinib, sotorasib, amivantamab, AZD3759, bintrafusp alfa, BPI-7711, Cabometyx, camrelizumab, canakinumab, cemiplimab, CS-1001, D-0316, Enhertu, ensartinib, HS-10296, lazertinib, Lenvima, Lynparza, mobocertinib, Tedopi, pyrotinib, repotrectinib, SAR408701, savolitinib, sintilimab, sitravatinib, tiragolumab, tislelizumab, and toripalimab. Several of these agents have demonstrated impressive clinical efficacy and are positioned to tackle unmet clinical needs in the treatment of NSCLC. GlobalData anticipates the launch of these agents to be the major driver of market growth across the 8MM.
Furthermore, KOLs are enthusiastic about clinical data demonstrating the efficacy of the first-in-class agents expected to enter the pipeline and novel combinatorial regimens to boost the efficacy of IO approaches. The increasing use of targeted agents and IO will gradually replace the use of generic chemotherapies in the metastatic setting, and eventually in the earlier settings during the forecast period. These factors will act as a major driver of market growth.
For more insights on NSCLC market drivers and challenges, download a sample report
NSCLC Market - Unmet Needs and Opportunities Assessment
The treatment of NSCLC is characterized by a significant level of unmet need despite progress in recent years in the treatment and personalization of therapy options. Unmet needs include both environmental and clinical needs and have been highlighted by KOLs across the 8MM. Specifically, the development of tyrosine kinase inhibitors for an array of distinct molecular aberrations, in addition to the introduction of checkpoint inhibitors in the first-line metastatic setting, have led to sustained and durable responses for patients with advanced disease.
For more insights on unmet needs and opportunities in the NSCLC market, download a sample report
NSCLC Market - Pipeline Assessment
The late-stage NSCLC pipeline demonstrates strong innovation in the field. A total of 29 agents are in late-stage clinical development (defined as a Phase III or potentially pivotal Phase II trial) and are expected to launch during the forecast period of 2019-2029 across the 8MM. Specific examples include novel agents targeting EGFR, ALK, and ROS1 mutations. In the immunotherapy space, there are also significant developments with several companies focusing their R&D strategies on developing combinatorial regimens of either targeted or immunomodulatory agents with checkpoint inhibitors, in the first-line or second-line settings. This strategy aims to further improve efficacy observed with ICIs with or without chemotherapy in patients with NSCLC and to steal market share in a particularly large and lucrative patient population.
For more insights on the NSCLC drugs pipeline and forecast, download a sample report
NSCLC Market - Competitive Landscape
The current marketed drug landscape in NSCLC includes a mix of targeted therapies, immunotherapies, and chemotherapies. In terms of classes of agents, TKIs and ICIs dominate the market. The NSCLC market can also be differentiated based on histology, as the squamous setting is largely dominated by ICIs compared to the non-squamous setting, which includes a mix of both TKIs and ICIs.
The current major players in NSCLC are Merck & Co., Roche, BMS, AstraZeneca, and Eli Lilly. Each player has either a single very successful agent or a successful portfolio in NSCLC. Specifically, each has developed and successfully commercialized drugs that either occupy a best-in-class status, often utilizing a first-to-market advantage, and have successfully innovated in a large patient population.
Leading Companies in the NSCLC Market
Merck & Co.
Roche
BMS
AstraZeneca
Eli Lilly
Novartis
Pfizer
Boehringer Ingelheim
To know more about leading companies in the NSCLC market, download a sample report
NSCLC Market Report Scope
Overview of NSCLC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline NSCLC market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting NSCLC therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global NSCLC therapeutics market from 2019-2029.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Related Reports
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type, and Key Players, 2022 Update – Click here
Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
NSCLC Drugs Market Overview
Market Size 2019 | $19.2 billion |
CAGR (2019-2029) | >5% |
Leading Companies | Merck & Co., Roche, BMS, AstraZeneca, Eli Lilly, Novartis, Pfizer, Boehringer Ingelheim, and Others |
FAQs
What was the NSCLC market size in 2019?
The NSCLC market size was valued at $19.2 billion in 2019.
What is the NSCLC market growth rate?
The NSCLC market is expected to grow at a CAGR of more than 5% during the forecast period.
Which are the leading companies in the NSCLC market?
The leading companies in the NSCLC market are Merck & Co., Roche, BMS, AstraZeneca, Eli Lilly, Novartis, Pfizer, and Boehringer Ingelheim.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 NSCLC: Executive Summary
2.1 The NSCLC Market Will Expand to $32.9B in 2029
2.2 Targeting Large Patient Populations in the First Line, with a Focus on Establishing New Actionable Mutations and Label Expansions for Premium Products into Earlier Lines
2.3 Opportunities Remain for Tackling Primary and Acquired Resistance to Targeted and IO Based Therapies
2.4 First-in-Class Approvals for Novel Actionable Mutations and Targeting Resistance
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Incident Cases of NSCLC
5.4.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
5.4.5 Diagnosed Incident Cases of NSCLC by Histological Types
5.4.6 Mutations Among Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma
5.4.7 Five-Year Diagnosed Prevalent Cases of NSCLC
5.5 Epidemiological Forecast for NSCLC, 2019–2029
5.5.1 Diagnosed Incident Cases of NSCLC
5.5.2 Sex-Specific Diagnosed Incident Cases of NSCLC
5.5.3 Age-Specific Diagnosed Incident Cases of NSCLC
5.5.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
5.5.5 Diagnosed Incident Cases of NSCLC by Histological Type
5.5.6 Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Mutations: Genomic Biomarkers, EGFR and KRAS Mutations
5.5.7 Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations
5.5.8 Five-Year Diagnosed Prevalent Cases of NSCLC
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 COVID-19 Impact
5.6.3 Limitations of the Analysis
5.6.4 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
6.5 China
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Increased Education, Application, and Refinement of Comprehensive Molecular Testing
8.3 Primary and Acquired Resistance to Immunotherapy
8.4 Personalized Approaches to Tackling Resistance
8.5 Improving Curative Options and Patient Outcomes for Those Without Actionable Mutations
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Merck & Co.
10.4 AstraZeneca
10.5 Roche
10.6 Eli Lilly
10.7 BMS
10.8 Pfizer
10.9 Boehringer Ingelheim
10.10 Novartis
10.11 Future players
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers – Global Issues
11.2 5EU
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 Japan
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 US
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research – KOLs Interviewed for This Report
12.4.1 KOLs
12.5 Primary Research – Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
About GlobalData
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
